Form 4: NeuroPace Inc. Executive Martha Morrell Sells Shares Under 10b5-1 Plan

Chief Medical Officer Martha Morrell of NeuroPace Inc. sold shares of common stock on February 21, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 21, 2025, Martha Morrell, Chief Medical Officer of NeuroPace Inc., sold 3,659 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $13.7213, with individual prices ranging from $13.25 to $14.21.
• Following the transaction, Morrell directly owns 78,334 shares of NeuroPace Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Positives

• The sale was executed under a pre-arranged 10b5-1 trading plan, which is often viewed as a way to avoid accusations of insider trading.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Sales under 10b5-1 plans are generally less indicative of immediate sentiment as they are pre-arranged.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates